Delivery Order SPE2DB22D1202-SPE2DB25FVGE2
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,683.45 to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets in quantities of 90. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded procurement. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of July 29, 2025. This award represents a routine...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp valued at $2,400.84 for the supply of Losartan-HCTZ 100-12.5 mg tablets in 90-count packages. This contract, awarded on August 1, 2025, with an ultimate completion date of August 4, 2025, represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award status. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a $5,910.20 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets in quantities of 90 units. This firm fixed-price delivery order, which is not set-aside designated, is set to complete on July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal medical supply...
- The Defense Logistics Agency awarded a $2,162.93 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Losartan-HCTZ 50-12.5 mg tablets (90-count supply) on August 7, 2025, with a completion date of August 8, 2025. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $19,748.97 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets in a quantity of 90 units. The contract employs firm fixed-price pricing with no set-aside designation and is scheduled for completion by July 28, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $3,436.44 firm fixed-price delivery order contract (SPE2DX15D3015|SPE2DX24F0EN0) to AmerisourceBergen Drug Corp for the supply of 4,563,434,205 units of Losartan-HCTZ 50-12.5 mg tablets. This delivery order is part of a larger $999,999,999 indefinite delivery contract (IDC) held by AmerisourceBergen with the DLA, which provides a comprehensive range of pharmaceutical products and medical supplies to support military...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets in a quantity of 90 units, with a ceiling value of $2,609.93. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The order is set for ultimate completion on July 22, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a $2,400.91 firm fixed price delivery order to AmerisourceBergen Drug Corp for 90 tablets of Losartan-HCTZ 100-12.5 mg, a common antihypertensive medication combining a angiotensin II receptor blocker with a thiazide diuretic. The order was competitively awarded with no set-aside designation and is scheduled for completion by July 21, 2025. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- This federal contract award, valued at $1,513.08, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Losartan-HCTZ 100-25 mg tablets in 90-count packages. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with DLA Troop Support Medical, which serves as a primary vehicle for providing...
- This is a $1,215.24 firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Losartan-HCTZ 50-12.5 mg tablets, a cardiovascular medication, to support military healthcare programs. The award is not designated as a set-aside contract. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVGE2Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for pharmaceutical supplies, specifically Losartan-HCTZ 50-12.5 mg tablets (90-count), valued at $2,297.83 with a firm fixed price structure. The award, issued on August 1, 2025, is set to complete by August 4, 2025. This is a non-set-aside competitive award with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion global pharmaceutical support vehicle extending through December 2026 that enables the contractor to supply pharmaceutical products and medical supplies to military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, is a critical federal vendor for military and veteran healthcare systems. The company maintains an extensive portfolio of federal contract awards with DLA and the Defense Health Agency, supplying a comprehensive range of medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. This particular order for Losartan-HCTZ, an antihypertensive medication, represents routine pharmaceutical procurement fulfillment under the contractor's established DLA relationship, demonstrating the vendor's ongoing role in supporting federal medical supply chain requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 8/1/25 |